Delphia Therapeutics

Executive Summary

Delphia Therapeutics is a preclinical-stage RNA therapeutics company developing novel treatments for oncology by targeting historically undruggable pathways in cancer. Founded in 2021 and headquartered in Cambridge, MA, the company has raised $67 million in total funding. Its proprietary RNA technology platform aims to address key challenges in drug discovery, enabling the modulation of targets that have been difficult to address with conventional small molecules or biologics. Delphia's pipeline is entirely in the discovery and preclinical stages, with no disclosed lead candidates or clinical timelines yet. The company operates in a competitive landscape of RNA-based oncology startups but differentiates itself through its focus on undruggable targets and its novel mechanism of action. Given the early stage, significant milestones such as IND-enabling studies and lead candidate nomination are critical for advancing the pipeline. The company's success hinges on demonstrating preclinical proof-of-concept and securing additional funding to support clinical development.

Upcoming Catalysts (preview)

• Q4 2026Lead candidate nomination for lead program60% success
• Q2 2026Presentation of preclinical efficacy data at a major oncology conference70% success
• H1 2027Series B financing or partnership deal50% success